Expanded Access Postings Not Promotional, Unless Done In ‘Promotional Context,’ US FDA Says
Executive Summary
Updated guidance on expanded access program clarifies that sponsors do not risk enforcement for off-label promotion if they post investigational drug expanded access policies, although that fear already may have subsided.
You may also be interested in...
Expanded Access: US FDA Application Data Suggest More Project Facilitate Outreach Needed
Academic medical centers still submit the vast majority of applications to the FDA Oncology Center of Excellence’s expanded access program, suggesting many community hospitals and other providers may perceive barriers to the program.
‘Expanded Access’ Is Not Unfettered Access
US FDA’s updated Q&A guidance on Expanded Access places greater emphasis on safeguards around emergency use and Treatment IND programs – a change in tone from the version finalized during the ‘Right To Try’ debate.
Comparative Claims In Product Promotions: FDA Isn’t Entirely Leaving It To Firms To ‘Duke It Out’
Four years after Woodcock’s famous comments, OPDP notes it is evaluating comparative claims as indicated in a recent untitled letter. DOJ is also looking at comparative claims. New FDA guidances are in the works, but it remains unknown when they will issue.